KRSA (KRSA) Operating Margin: Latest Data, Historical Trends & Peer Comparison
What is KRSA's (KRSA) Operating Margin?
For the trailing twelve months (TTM) ended Dec 31, 2025, KRSA Operating Margin was -239.78%, representing a -- change year over year.
For fiscal Q4'25 ended Dec 31, 2025, KRSA Operating Margin was -81.76%, representing a -394.13% change year over year.
For fiscal FY'25 ended Dec 31, 2025, KRSA Operating Margin was -239.78%, representing a -32.18% change year over year.
Operating Margin Historical Trend for KRSA
View KRSA's annual, quarterly, and TTM Operating Margin data from 2019 to 2025, including historical growth rates and trend analysis.
KRSA TTM Data
| Metric | Q2'20Jun 30, 2020 | Q3'20Sep 30, 2020 | Q4'20Dec 31, 2020 | Q1'21Mar 31, 2021 | Q2'21Jun 30, 2021 | Q3'21Sep 30, 2021 | Q4'21Dec 31, 2021 | Q1'22Mar 31, 2022 | Q2'22Jun 30, 2022 | Q3'22Sep 30, 2022 | Q4'22Dec 31, 2022 | Q1'23Mar 31, 2023 | Q2'23Jun 30, 2023 | Q3'23Sep 30, 2023 | Q3'25Sep 30, 2025 | Q4'25Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Margin YoY | -2.04K% -- | -2.43K% -- | -3.54K% -- | -5.51K% -- | -1.96K% +3.94% | -1.70K% +30.26% | -1.40K% +60.44% | -1.19K% +78.35% | -2.74K% -39.74% | -3.31K% -95.35% | -2.73K% -95.02% | -4.20K% -252.35% | -4.81K% -75.31% | -3.12K% +5.82% | -127.25% -- | -239.78% -- |
KRSA Quarterly Data
| Metric | Q2'19Jun 30, 2019 | Q3'19Sep 30, 2019 | Q4'19Dec 31, 2019 | Q1'20Mar 31, 2020 | Q2'20Jun 30, 2020 | Q3'20Sep 30, 2020 | Q4'20Dec 31, 2020 | Q1'21Mar 31, 2021 | Q2'21Jun 30, 2021 | Q3'21Sep 30, 2021 | Q4'21Dec 31, 2021 | Q1'22Mar 31, 2022 | Q2'22Jun 30, 2022 | Q3'24Sep 30, 2024 | Q4'24Dec 31, 2024 | Q1'25Mar 31, 2025 | Q2'25Jun 30, 2025 | Q3'25Sep 30, 2025 | Q4'25Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Margin YoY | -2.03K% -- | -2.00K% -- | -1.80K% -- | -2.03K% -- | -2.63K% -29.36% | -5.45K% -171.71% | -14.45K% -705.18% | -21.60K% -964.03% | -539.20% +79.47% | -3.24K% +40.44% | -2.69K% +81.39% | -1.83K% +91.55% | -4.39K% -714.14% | -581.44% -- | 27.80% -- | -1.80K% -- | -1.80K% -- | -114.97% +80.23% | -81.76% -394.13% |
KRSA Annual Data
| Metric | FY'19Dec 31, 2019 | FY'20Dec 31, 2020 | FY'21Dec 31, 2021 | FY'22Dec 31, 2022 | FY'24Dec 31, 2024 | FY'25Dec 31, 2025 |
|---|---|---|---|---|---|---|
Operating Margin YoY | -2.77K% -- | -3.54K% -27.58% | -1.40K% +60.44% | -6.24K% -345.83% | -181.40% -- | -239.78% -32.18% |
KRSA (KRSA) : Definition & Explanation
Operating Margin shows how much of each dollar of revenue remains at a particular step of the income statement or cash flow profile.
It matters because operating margin can reveal pricing power, cost discipline, business mix, and whether growth is turning into real economic value.
This is usually a calculated ratio. The numerator is a profit or cash flow measure, and the denominator is revenue for the same period.
Investors often compare operating margin across time, against peers, and alongside revenue growth. A rising margin can be encouraging, but it is worth checking whether the change came from healthy operating improvement, temporary mix shifts, or one-off items.
KRSA (KRSA) Operating Margin vs Competitors | Chemical Pharmaceuticals Comparison
Compare KRSA's (KRSA) Operating Margin with competitors. View latest market cap and Operating Margin performance.
| Ticker | Company | Market Cap | Operating Margin |
|---|---|---|---|
| LLY | Eli Lilly | 1.08T | 47.90% |
| JNJ | Johnson & Johnson | 651.20B | 26.81% |
| ABBV | Abbvie | 466.55B | 24.41% |
| NVS | Novartis | 267.85B | 30.43% |
| NVO | Novo Nordisk | 190.81B | 45.29% |
| BMY | Bristol-Myers Squibb | 128.36B | 28.86% |
| SNY | Sanofi | 104.75B | 13.18% |
| GSK | GSK | 103.28B | 24.45% |
| TAK | Takeda Pharmaceutical | 60.21B | -0.01% |
| TEVA | Teva Pharmaceutical | 45.71B | 13.20% |
| ONC | Beone Medicines | 40.19B | 11.95% |
| RPRX | Royalty Pharma | 33.88B | 59.61% |
| VTRS | Viatris | 19.68B | 0.96% |
| JAZZ | Jazz Pharmaceuticals | 15.83B | 19.49% |
| NBIX | Neurocrine Biosciences | 15.43B | 25.43% |
| EXEL | Exelixis | 14.49B | 39.43% |
| CORT | Corcept Therapeutics | 12.42B | -1.07% |
| MDGL | Madrigal | 12.35B | -27.68% |
| AXSM | Axsome Therapeutics | 11.22B | -24.45% |
| RDY | Dr. Reddy'S Laboratories | 10.17B | 10.91% |
| ALKS | Alkermes | 7.84B | 12.28% |
| BLTE | Belite Bio | 6.86B | -- |
| RYTM | Rhythm | 6.82B | -90.89% |
| MIRM | Mirum | 6.42B | -139.82% |
| BLCO | Bausch + Lomb | 5.99B | 4.40% |
| AMRX | Amneal | 5.84B | 14.30% |
| LGND | Ligand | 5.68B | 34.46% |
| DFTX | Definium | 5.20B | -- |
| AMLX | Amylyx | 4.26B | -- |
| TLX | Telix | 4.25B | 3.70% |
KRSA (KRSA) Operating Margin Related Metrics
Explore key financial metrics related to KRSA's (KRSA) Operating Margin. Click on the links below to dive deeper into similar and complementary indicators.
About KRSA (KRSA)
KRSA
Industry
--
Established Date
--
Listing Date
--
Exchange
--
Full-time Employees
--
Fiscal Year Ends
--
Website
--
Security Type
--
Office address
--
Business
--
Introduction
--